Investor Relations

Joining the Adamis Board of Directors, Dr. Tina S. Nova Ph.D. and CEO of Genoptix, Inc, states:

Adamis’ goal is to lay the foundation to become one of the leading biopharmaceutical companies in the medical arena. We are attempting to accomplish this by focusing our efforts on producing products that help treat life-threatening diseases, help mankind attain a better quality of life, and at the same time, create substantial shareholder value.

SEC Filings

Click here for SEC filings on the company.

Forward-Looking Statement

This website includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts, but are based on current expectations, assumptions, estimates and beliefs about our company and our industry. These statements are often, but not always, made through the use of word or phrases such as “believe,” “will,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” and “would.” Statements throughout this website concerning future events depend on several factors beyond the company’s control, including receipt of adequate funding to support these activities. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, one or more of which may cause our actual results to be materially different from the forward-looking statements contained throughout this website.

Forward-looking statements contained on this website may include, but are not limited to, statements about Adamis’ product candidates, research and development, strategies, objectives regulatory matters, markets, and future performance, as well as statements about the following matters: the benefits of Adamis’ strategic relationship with Beximco; future financial and operating results; the company’s ability to obtain adequate funding to support its operations; the company’s beliefs concerning the safety and effectiveness of its compounds and drug product candidates; the expected timing and outcome of future clinical trials of the company’s product candidates; the expected timing and outcome of submissions to the FDA or other regulatory agencies for approvals to conduct clinical trials or for marketing approvals for our products; future revenues from sales of products, assuming that they are developed and approved for marketing by the FDA and other regulatory authorities; the current or future market sizes for the company’s products and the extent of customer demand for the company’s products; our ability to acquire other compounds and product candidates; and the intellectual property protection that may be afforded by any patents or patent applications relating to Adamis’ products, product candidates and technologies.

The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: Adamis’ inability to obtain required funding, which could delay or prevent research, development and commercialization of its products; the possibility that the expected synergies from Adamis’ relationship with Beximco will not be realized, or will not be realized within the expected time period; unexpected developments at the FDA or other regulatory agencies; the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry; the fact that many of Adamis’ products are in the early stages of development, and future clinical trials may not demonstrate the safety or effectiveness of its product candidates; future market conditions and demand for Adamis’ products may be materially different from expectations; Adamis may be subject to adverse regulatory actions; patents and intellectual property may not be effective to protect Adamis’ rights in its products or prevent other from developing competing products, or third parties may have patents or intellectual property that restrict Adamis’ ability to commercialize and sell products; the risk of new and changing regulation and health policies in the U.S. and internationally; and Adamis’ exposure to litigation and unexpected outcomes in litigation. Additional risks not known to Adamis or that Adamis believes are immaterial may also adversely affect its business, operating results and financial condition and the value of an investment in its securities.

A more complete description of these and other risks and uncertainties that could cause actual results and events to differ materially from the outcomes anticipated by forward-looking statements is set forth under the caption "Risk Factors" contained in our annual report on Form 10-K (Part I, Item 1A) and in other reports Adamis files with the with the Securities and Exchange Commission (SEC), which are available at the SEC’s Internet site (www.sec.gov). Adamis strongly urges you to read and consider each of those factors when evaluating the forward-looking statements.

No Duty to Update